Larger randomized controlled trials with diverse populations and longer follow-up are required to ensure generalizability across a wider target population and to determine whether it is a cost-effective approach that provides sustained benefits for people with type 2 diabetes requiring insulin therapy. This evidence concerns the gene INS and type 2 diabetes mellitus.